The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 23, 2021

Filed:

Jul. 23, 2013
Applicant:

Pharmacyclics Llc, Sunnyvale, CA (US);

Inventors:

Betty Chang, Cupertino, CA (US);

Joseph J. Buggy, Mountain View, CA (US);

Susanne M. Steggerda, San Francisco, CA (US);

Assignees:

Pharmacyclics LLC, Sunnyvale, CA (US);

Cornell University, Ithaca, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 45/06 (2006.01); C07K 14/00 (2006.01); C12N 9/12 (2006.01); C12N 9/16 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 45/06 (2013.01); C07K 14/00 (2013.01); C12N 9/12 (2013.01); C12N 9/16 (2013.01); G01N 33/5041 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/16 (2013.01); C12Y 207/10002 (2013.01); C12Y 301/04011 (2013.01);
Abstract

Described herein are mutations that confer resistance to treatment with a BTK inhibitor. Described herein are modified BTK polypeptides that exhibit decreased inhibition (i.e. are resistant) to a covalent and/or irreversible BTK inhibitor. Also described herein modifications of PLCy2 and CARD 11 polypeptides that confer resistance to treatment with a BTK inhibitor. Described herein are diagnostic methods for detecting the modified polypeptides and nucleic acids encoding the modified polypeptides and applications of the methods thereof. Described herein are compositions, combinations, and kits containing the modified polypeptides and methods of using the modified polypeptides. Also described herein are methods of using modified BTK polypeptides as screening agents for the identification and design of second-generation BTK inhibitors.


Find Patent Forward Citations

Loading…